In summary, our results provide promise for the use of tMUC1-CAR T cells against treatment refractory PDA in combination with inhibitors against IDO1, COX1/2, and Gal-9 or in combination with low-dose standard chemotherapy drugs. This evidence concerns the gene PTGS1 and Patent ductus arteriosus.